Vasculogenic mimicry in neuroendocrine tumour across different primary sites

#4564

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Aim(s): To assess VM in NET across different primary sites.

Materials and methods: Patients diagnosed with NET were retrospectively enrolled from Fudan University Shanghai Cancer Center. Sections of tumour were collected for CD31 and Periodic acid–Schiff (PAS) dual-staining. The whole sections were assessed for the presence of VM (vessels with CD31-negative but PAS positive and lined with tumour cells).

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,